MARKET

IMNN

IMNN

Imunon Inc
NASDAQ
3.630
+0.480
+15.24%
After Hours: 3.671 +0.041 +1.13% 19:56 12/29 EST
OPEN
3.120
PREV CLOSE
3.150
HIGH
4.000
LOW
2.990
VOLUME
299.90K
TURNOVER
--
52 WEEK HIGH
47.40
52 WEEK LOW
2.990
MARKET CAP
11.15M
P/E (TTM)
-0.3559
1D
5D
1M
3M
1Y
5Y
1D
Imunon CEO Says As We Enter 2026, Imunon Is Poised For Key Milestones, Including Continued Enrollment In OVATION 3 With Interim Analyses Potentially Enabling Early Stopping And BLA Filing In The HRD+ Population
Benzinga · 11h ago
Imunon CEO says ‘poised for key milestones’ as company enters 2026
TipRanks · 11h ago
Imunon Advances Pivotal Phase 3 OVATION 3 Study for IMNN-001 in Ovarian Cancer
Reuters · 11h ago
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
Barchart · 17h ago
Weekly Report: what happened at IMNN last week (1222-1226)?
Weekly Report · 17h ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at IMNN last week (1215-1219)?
Weekly Report · 12/22 10:06
Weekly Report: what happened at IMNN last week (1208-1212)?
Weekly Report · 12/15 10:12
More
About IMNN
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

Webull offers Imunon Inc stock information, including NASDAQ: IMNN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMNN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMNN stock methods without spending real money on the virtual paper trading platform.